GENE ONLINE|News &
Opinion
Blog

Kite Pharma
Trials & Approvals CAR T-cell Therapy
Gilead’s Breakthrough CAR-T Becomes First to Get FDA Approval for Indolent Follicular Lymphoma
2021-03-07
Trials & Approvals
Kite Presents Yescarta’s Encouraging Long Term ZUMA-1 Trial Results at ASH2020
2020-12-06
Trials & Approvals CAR T-cell Therapy
First and Only CAR T Therapy for Mantle Cell Lymphoma Gets FDA Nod
2020-07-30
R&D Cancer
Gilead, Kite, and oNKo-innate Collaborate to Advance Cancer Immunotherapy Using NK Cells
2020-04-26
Licensing Multiple Myeloma
Kite Pharma Licences Teneobio’s Antibody Platform to Fight Multiple Myeloma
2020-04-03
Daiichi Sankyo Seeks Yescarta Approval in Japan for Relapsed or Refractory B-cell Lymphoma
2020-04-01
M&A CD47
Gilead Strikes US$ 4.9B Takeover Deal of Forty Seven
2020-03-02
IPO Acute Lymphoblastic Leukemia
Tracking “OFF THE SHELF” CAR-T Cell therapy & an IPO worth $100M
2018-10-15
1 2
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top